Adverum Biotechnologies: Ocular and rare disease gene therapy company. Lead program, ADVM-022, currently in a Phase 1 study in wAMD. Preclinical programs in A1AT deficiency and HAE. Collaborations in place with Regeneron and Editas.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Ophthalmology, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM +
Therapeutic Modalities
Gene Therapy
Website:
Address:
1035 O'Brien Drive
Menlo Park, CA 94025
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.